Floatz logo

ZIPRASIDONE

Delusional Disorder

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Small moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Delusional Disorder cohort.

Asset / SponsorPhaseRating
Agomelatine
Central Institute of Mental Health, Mannheim
Phase 4BB
Dcs
NYU Langone Health
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Uppsala University Hospital
Phase 2CCC
BENZTROPINE
Centre for Addiction and Mental Health
N/AD
Risperdal
Centre for Addiction and Mental Health
N/AD
Olanzapine
Centre for Addiction and Mental Health
N/AD

Same molecule, other indications

ZIPRASIDONE is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
76 / 100
View asset →
Depression, BipolarDormant
BBB
Indicative ·
73 / 100
View asset →
psychotic disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →